These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38427337)

  • 1. Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel.
    Sax PE; Thompson MA; Saag MS;
    JAMA; 2024 Mar; 331(12):1060-1061. PubMed ID: 38427337
    [No Abstract]   [Full Text] [Related]  

  • 2. Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.
    Barnett SK; Armas-Kolostroubis L; Sension M; Riedel DJ
    AIDS; 2022 Aug; 36(10):1475-1476. PubMed ID: 35876710
    [No Abstract]   [Full Text] [Related]  

  • 3. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
    Blackwell CW; López Castillo H
    J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
    Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
    Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.
    Brock JB; Herrington P; Hickman M; Hickman A
    Clin Infect Dis; 2024 Jan; 78(1):122-124. PubMed ID: 37740255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabotegravir and Rilpivirine.
    Am J Health Syst Pharm; 2021 May; 78(11):925-931. PubMed ID: 33822851
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation.
    Wood BR; Kassaye SG; Gerstoft J
    AIDS; 2023 Mar; 37(4):689-691. PubMed ID: 36815522
    [No Abstract]   [Full Text] [Related]  

  • 9. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
    Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
    Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice.
    Borghetti A; Farinacci D; Ciccullo A; Dusina A; Moschese D; Iannone V; D'Angelillo A; Lombardi F; Donne VD; Massaroni V; Visconti E; Tamburrini E; Di Giambenedetto S
    J Med Virol; 2022 Oct; 94(10):4970-4974. PubMed ID: 35638227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
    Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
    J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir/rilpivirine initiation program.
    Masich AM; Gomes D; Higginson RT; Morgan Z; Nixon D; Tran M; Winthrop E; Fulco PP
    AIDS; 2023 Aug; 37(10):1641-1642. PubMed ID: 37450631
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the
    Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First Extended-Release Injectable Drug Therapy for HIV.
    Aschenbrenner DS
    Am J Nurs; 2021 May; 121(5):24-25. PubMed ID: 33872258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.
    Scheibe K; Urbańska A; Serwin K; Parczewski M
    Infect Genet Evol; 2022 Oct; 104():105358. PubMed ID: 36057423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of long-acting cabotegravir + rilpivirine during hemodialysis and solid organ transplantation.
    Rezzonico LF; Baldassari L; Peracchi F; Merli M; Puoti M; Rossotti R
    AIDS; 2023 Jul; 37(9):1491-1493. PubMed ID: 37395256
    [No Abstract]   [Full Text] [Related]  

  • 17. APOBEC-Induced Mutations at Initiation of Cabotegravir + Rilpivirine for Two Patients Infected by HIV-1 Subtype CRF02: The Interest of Systematic Genotyping.
    Wembulua BS; Valin N; Lambert-Niclot S; Nerozzi-Banfi E; Chiarabini T; Meynard JL; Lacombe K
    J Acquir Immune Defic Syndr; 2023 Mar; 92(3):e17-e18. PubMed ID: 36729654
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV".
    Han K
    Antimicrob Agents Chemother; 2024 May; 68(5):e0020424. PubMed ID: 38534102
    [No Abstract]   [Full Text] [Related]  

  • 19. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
    Zeuli JD; Rivera CG; Smith BL; Otto A; Temesgen Z
    Drugs Today (Barc); 2022 Dec; 58(12):555-576. PubMed ID: 36651065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV.
    Qazzaz H; Parganas C; Cory TJ
    Expert Opin Pharmacother; 2022 Sep; 23(13):1485-1495. PubMed ID: 36124818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.